A pharmacy-prepared version of tirzepatide that is not FDA-approved and not the same as Zepbound or Mounjaro.
Compounded tirzepatide is prepared by a licensed pharmacy. It is not FDA-approved and not the same as Zepbound or Mounjaro. Quality depends on the pharmacy; many products are multi-dose vials requiring careful self-measurement. With the shortage resolved, lawful compounding is now narrow.
| What to know |
|---|
| A pharmacy-prepared version of tirzepatide that is not FDA-approved and not the same as Zepbound or Mounjaro. |
| Compounded tirzepatide is prepared by a licensed pharmacy. |
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.